MeSH term
Frequency | Condition_Probility | Adult | 27 | 0.0 |
Aged | 30 | 0.0 |
Aged, 80 and over | 7 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 6 | 1.0 |
Female | 46 | 0.0 |
Humans | 69 | 0.0 |
Male | 42 | 0.0 |
Middle Aged | 40 | 0.0 |
Neoplasm Staging | 4 | 0.0 |
Prognosis | 4 | 0.0 |
Animals | 6 | 0.0 |
Antigens, CD/metabolism | 2 | 0.0 |
Dogs | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 13 | 0.0 |
Retrospective Studies | 4 | 0.0 |
Biopsy | 8 | 0.0 |
*Chromosome Aberrations | 2 | 0.0 |
Immunohistochemistry | 11 | 0.0 |
Karyotyping | 4 | 0.0 |
Liver/pathology | 3 | 1.0 |
Chromosome Banding | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 5 | 0.0 |
Uterus/*blood supply | 2 | 8.0 |
Vascular Diseases/*pathology | 3 | 75.0 |
Veins/pathology | 3 | 42.0 |
Antigens, CD/analysis | 2 | 0.0 |
Combined Modality Therapy | 2 | 0.0 |
Tumor Markers, Biological/analysis | 2 | 0.0 |
Dementia/etiology | 2 | 28.0 |
Fatal Outcome | 13 | 2.0 |
Antigens, CD20/metabolism | 2 | 9.0 |
Autopsy | 3 | 1.0 |
Bone Marrow Cells/*pathology | 2 | 8.0 |
Bone Marrow Examination | 2 | 5.0 |
Cytogenetic Analysis | 3 | 2.0 |
English Abstract | 9 | 0.0 |
Histiocytosis, Non-Langerhans-Cell/pathology | 2 | 66.0 |
Flow Cytometry | 3 | 0.0 |
Immunoglobulins, Heavy-Chain/analysis | 2 | 16.0 |
Immunophenotyping | 5 | 0.0 |
Remission Induction | 2 | 0.0 |
Biopsy, Needle | 4 | 0.0 |
Diagnosis, Differential | 12 | 0.0 |
Follow-Up Studies | 3 | 0.0 |
Treatment Outcome | 2 | 0.0 |
Vascular Neoplasms/drug therapy/*pathology | 2 | 100.0 |
Disease-Free Survival | 2 | 0.0 |
Neoplasm Invasiveness | 4 | 0.0 |
Skin Neoplasms/pathology | 2 | 8.0 |
Comparative Study | 4 | 0.0 |
Leiomyoma/*pathology | 4 | 44.0 |
Sensitivity and Specificity | 2 | 0.0 |
Uterine Neoplasms/*pathology | 6 | 26.0 |
Bone Marrow Cells/pathology | 2 | 3.0 |
Gene Rearrangement | 2 | 0.0 |
Survival Rate | 3 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 4 | 0.0 |
*Vena Cava, Inferior | 2 | 50.0 |
Magnetic Resonance Imaging | 4 | 0.0 |
Cauda Equina/*pathology | 2 | 66.0 |
Cyclophosphamide/administration & dosage | 2 | 0.0 |
Doxorubicin/administration & dosage | 2 | 1.0 |
Vincristine/administration & dosage | 2 | 1.0 |
Amino Acid Sequence | 2 | 0.0 |
Molecular Sequence Data | 2 | 0.0 |
Adolescent | 2 | 0.0 |
Vascular Neoplasms/*diagnosis/pathology | 2 | 66.0 |
Tomography, X-Ray Computed | 3 | 0.0 |
Vascular Neoplasms/*complications | 2 | 100.0 |
In Situ Hybridization | 3 | 0.0 |
Vascular Neoplasms/diagnosis/*pathology | 2 | 100.0 |
Veins/*pathology | 3 | 75.0 |
Vascular Neoplasms/*diagnosis | 2 | 100.0 |
Polymerase Chain Reaction | 2 | 0.0 |
Bone Marrow/*pathology | 2 | 1.0 |
Infusions, Intravenous | 2 | 0.0 |
Blood Vessels/*pathology | 2 | 18.0 |
Radiography, Thoracic | 2 | 5.0 |
